IL317011A - Crystalline forms of TYK2 inhibitors and their use - Google Patents

Crystalline forms of TYK2 inhibitors and their use

Info

Publication number
IL317011A
IL317011A IL317011A IL31701124A IL317011A IL 317011 A IL317011 A IL 317011A IL 317011 A IL317011 A IL 317011A IL 31701124 A IL31701124 A IL 31701124A IL 317011 A IL317011 A IL 317011A
Authority
IL
Israel
Prior art keywords
crystalline form
powder
ray diffraction
diffraction pattern
degrees
Prior art date
Application number
IL317011A
Other languages
English (en)
Hebrew (he)
Inventor
Kolbot By
Travis Remarchuk
Original Assignee
Alumis Inc
Kolbot By
Travis Remarchuk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alumis Inc, Kolbot By, Travis Remarchuk filed Critical Alumis Inc
Publication of IL317011A publication Critical patent/IL317011A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL317011A 2022-05-13 2023-05-12 Crystalline forms of TYK2 inhibitors and their use IL317011A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263341528P 2022-05-13 2022-05-13
US202263405577P 2022-09-12 2022-09-12
PCT/US2023/021986 WO2023220338A1 (en) 2022-05-13 2023-05-12 Crystalline forms of a tyk2 inhibitor and uses thereof

Publications (1)

Publication Number Publication Date
IL317011A true IL317011A (en) 2025-01-01

Family

ID=86760338

Family Applications (1)

Application Number Title Priority Date Filing Date
IL317011A IL317011A (en) 2022-05-13 2023-05-12 Crystalline forms of TYK2 inhibitors and their use

Country Status (11)

Country Link
EP (1) EP4522602A1 (enExample)
JP (1) JP2025516683A (enExample)
KR (1) KR20250009492A (enExample)
CN (1) CN119907791A (enExample)
AU (1) AU2023269081A1 (enExample)
CA (1) CA3253365A1 (enExample)
CL (1) CL2024003456A1 (enExample)
IL (1) IL317011A (enExample)
MX (1) MX2024014000A (enExample)
TW (1) TW202409007A (enExample)
WO (1) WO2023220338A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202428571A (zh) * 2022-10-10 2024-07-16 美商雅盧米斯公司 Tyk2抑制劑之晶型及其用途
WO2026019902A1 (en) * 2024-07-16 2026-01-22 Alumis Inc. Crystalline forms of a tyk2 inhibitor and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20250048T1 (hr) * 2018-10-22 2025-03-28 Alumis Inc. Inhibitori tyk2 i njihova uporaba

Also Published As

Publication number Publication date
KR20250009492A (ko) 2025-01-17
JP2025516683A (ja) 2025-05-30
CA3253365A1 (en) 2023-11-16
CL2024003456A1 (es) 2025-04-25
AU2023269081A1 (en) 2024-11-28
CN119907791A (zh) 2025-04-29
TW202409007A (zh) 2024-03-01
WO2023220338A1 (en) 2023-11-16
EP4522602A1 (en) 2025-03-19
MX2024014000A (es) 2025-02-10

Similar Documents

Publication Publication Date Title
TWI877197B (zh) Ｃｆｔｒ調節劑之結晶形式
TWI808108B (zh) N-(4-(4-(環丙基甲基)哌嗪-1-羰基)苯基)喹啉-8-磺醯胺之結晶型
CA3037986C (en) Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
EP3925960A1 (en) Fgfr inhibitor compound in solid form and preparation method therefor
WO2006088075A1 (ja) ピリジル 非芳香族含窒素ヘテロ環－１－カルボン酸エステル誘導体
NZ564409A (en) Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide hydrochloride
CA2900322A1 (en) Solid forms of the selective cdk4/6 inhibitor compound acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8h-pyrido[2,3-d]pyrimidin-7-one
CN116322676A (zh) Cftr调节剂的结晶形式
IL225808A (en) Sesquihydrate of 1-{(2s)-2-amino-4-[2,4-bis(trifluoromethyl)-5,8-di-hydropyrido[3,4-d]pyrimidin-7(6h)-yl]-4-oxobutyl}-5,5-difluoro-piperidin-2-one tartrate, process for its preparation and pharmaceutical compositions comprising it for treating diabetes and obesity
CA3253365A1 (en) CRYSTALLINE FORMS OF A TYK2 INHIBITOR AND THEIR USES
MX2011006782A (es) Sal de derivado de tetrahidrotriazolopiridina y un cristal de la misma.
US20250376459A1 (en) Crystalline forms of a tyk2 inhibitor and uses thereof
US20260138965A1 (en) Crystalline forms of a tyk2 inhibitor and uses thereof
IL315658A (en) Levodopa tyrosine polymorphs
JP2025535092A (ja) Ｔｙｋ２阻害剤の結晶形態及びその使用
WO2026019902A1 (en) Crystalline forms of a tyk2 inhibitor and uses thereof
WO2026019908A1 (en) Crystalline forms of a tyk2 inhibitor and uses thereof
IL295992A (en) Salts and polymorphic forms of 6-chloro-7-(4-(4-chlorobenzyl)piperazin-1-yl)-2-(1,3-dimethyl-1h-pyrazol-4-yl)-3h-imidazo[4,5-b]pyridine
TWI827429B (zh) 羰基橋連雜環類化合物、及其組合物與應用
TW202610624A (zh) Tyk2抑制劑之晶型及其用途
TW202610625A (zh) Tyk2抑制劑之晶型及其用途
HK40104405A (en) Crystalline forms of n-(4-(4-(cyclopropylmethyl) piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide
IL310339A (en) A method for the production of a monocyclic pyridine derivative
EA047596B1 (ru) Кристаллические формы модуляторов cftr
KR20210134065A (ko) 벤조티아졸 화합물의 약제학적 염, 다형체 및 이들의 제조 방법